Section 3 of 6
Product information and disease description
383 evidence topics · 249 sources
Product description
Phase of product development
Regulatory status: Under review; BLA submitted September 2026 under the accelerated approval pathway, with a PDUFA target action date in May 2027
Launch
No evidence found.
Commercial launch preparation
FDA acceptance of the BLA with Priority Review, November 2026
BLA submission in August 2026 and acceptance in October 2026: Form 10-Q statement
Advisory committee meeting tentatively planned
Confirmatory study: alignment with the FDA on key design elements, November 2026
BLA submission and priority review request, September 2026
Type B meeting minutes, July 2026
Type B meeting, June 2026
BLA submission timing: third quarter of 2026, June 2026, superseded in September 2026
FDA position after the January 2026 Type A meeting, March 2026, superseded in June 2026
Type A meeting scheduled, January 2026
Pre-BLA meeting minutes, December 2025
BLA submission timing: unclear, November 2025, superseded in June 2026
BLA submission timing: first quarter of 2026, June 2025, superseded in November 2025
U.S. launch timing: 2026, September 2025, superseded in November 2025
FDA interactions on the statistical analysis plan, 2025
FDA interactions on chemistry, manufacturing and controls, 2025
FDA alignment on the accelerated approval pathway, December 2024, superseded in November 2025
Designations held: current statement
Regenerative Medicine Advanced Therapy designation: May 2024
Orphan drug designation: FDA, September 2017
| Field | Quoted record |
|---|---|
| Generic name | “adeno-associated viral vector serotype 5 encoding a microRNA targeted to human huntingtin gene” |
| Date designated | “09/27/2017” |
| Orphan designation | “Treatment of Huntington's disease” |
| Orphan designation status | “Designated” |
| FDA orphan approval status | “Not FDA Approved for Orphan Indication” |
| Sponsor | “uniQure Biopharma B.V.” |
Orphan designation: European Commission, January 2018
PRIority MEdicines (PRIME) designation
No evidence found.
UK marketing authorization application: submitted and validated, third quarter of 2026
UK MAA timing: third quarter of 2026, April 2026, superseded in September 2026
European Union and other markets: statements on regulatory pathways
Investigational New Drug application effective, January 2019
Financing: cash position and runway into 2030, September 2026
Financing: Hercules term loan terms tied to BLA approval
Cash runway into the second half of 2029, March 2026, superseded in July 2026
Securities class action
Product information
Generic, brand name and therapeutic class of product
Nonproprietary name and development code
Nonproprietary name: WHO proposed International Nonproprietary Name and substance description
Product name, product code, and descriptive name in the EU clinical trial record
| Field | Quoted record |
|---|---|
| Product name | “rAAV5-miHTT” |
| Product code | “AMT-130” |
| Other descriptive name | “ADENO-ASSOCIATED VIRUS SEROTYPE 5 ENCODING A MICRORNA TARGETED TO HUMAN HUNTINGTIN GENE” |
Brand name
No evidence found.
Therapeutic class: AAV-based gene therapy using the miQURE gene-silencing platform
Licensing: miQURE platform technology from Cold Spring Harbor Laboratory
Intellectual property: patent families covering AMT-130 and its formulation
Manufacturing: contract manufacturing by Genezen after the 2024 facility sale
Dosage forms and strengths
Pharmaceutical form and route of administration
| Field | Quoted record |
|---|---|
| Active substance | “ifezuntirgene inilparvovec” |
| Condition | “Treatment of Huntington’s disease” |
| Pharmaceutical form | “Suspension for infusion” |
| Route of administration | “INTRACEREBRAL USE” |
| Applicant | “uniQure biopharma B.V.” |
Pharmaceutical form and concentrations in the European phase Ib/II study
| Field | Quoted record |
|---|---|
| Pharmaceutical form | “Solution for infusion” |
| Concentration, first IMP | “2 x 10e12 gc/mL” |
| Concentration, second IMP | “2 x 10e13 gc/mL” |
Dose levels administered in the phase I/II studies: vector genomes per participant
Formulation composition, fill volume, and storage conditions
No evidence found.
Average sales price and wholesale acquisition cost
Not applicable.
American hospital formulary service (AHFS), or other drug classification
WHO International Nonproprietary Name classification
U.S. regulatory classification: biologic and gene therapy reviewed by CBER
AHFS and Anatomical Therapeutic Chemical classification
No evidence found.
Indication
Indication submitted in the BLA: treatment of Huntington's disease under the accelerated approval pathway
Investigational status: no approved indication
Population studied: adults aged 25 to 65 years with early manifest Huntington's disease
Pharmacology
Mechanism of action
Mechanism: AAV5 vector carrying a microRNA that non-selectively lowers human huntingtin
Non-selective huntingtin knockdown: company description of the construct
miQURE platform: degradation of disease-causing transcripts and secondary exosome-mediated silencing
Mechanistic goals of the phase I/II studies: biodistribution and durable knockdown of huntingtin and exon 1 huntingtin
Axonal transport of the vector to other brain regions affected by the disease
Construct attributes stated by the sponsor: suppression of huntingtin and of the exon 1 isoform
Construct design: targeting of huntingtin exon 1 and total silencing of both alleles
“In the first approach, total silencing of wild-type and mtHTT was achieved by targeting exon 1.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Twenty-one miHTT variants were designed to target HTT exon 1.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For the first time, we show that the therapeutic pri-miRNA scaffold influences HTT knock-down and guide strand processing in vivo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Scaffold selection and absence of passenger strand activity in vitro
Suppression of mutant huntingtin aggregates and neuronal dysfunction in a lentiviral rat model
“Our data demonstrated suppression of mutant HTT messenger RNA, which almost completely prevented mutant HTT aggregate formation, and ultimately resulted in suppression of DARPP-32-associated neuronal dysfunction.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Ultimately, AAV5-delivered-miRNA-mediated HTT lowering did not cause activation of microglia or astrocytes suggesting no immune response to the AAV5 vector or therapeutic precursor sequences.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Continuous microRNA expression after a single vector administration
“Importantly, the AAV-delivered-miRNA-based gene therapy approach comprises continual expression of artificial miRNAs following a single administration of an AAV vector, resulting in long-term HTT lowering.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Rationale for lowering huntingtin messenger RNA rather than the protein
“miRNA-based lowering strategies are designed to lower HTT mRNA levels and thereby reduce the overall mutant HTT protein.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The latter is crucial for assessment of tolerability of non-selective HTT lowering, in which case the remaining levels of endogenous HTT are relevant.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cell types transduced by AAV5 after intracranial injection
Off-target assessment in patient-derived neurons and astrocytes
“Small RNA sequencing showed that mature miHTT was processed correctly without off-target passenger strand.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“No cellular microRNAs were dysregulated, indicating that endogenous RNAi machinery was unaffected by miHTT overexpression.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“qPCR validation of in silico-predicted off-target transcripts, next-generation sequencing, and pathway analysis confirmed absence of dysregulated genes due to sequence homology or seed-sequence activity of miHTT.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Non-allele-selective lowering: tolerability of wild-type huntingtin reduction in humanized mice
“Importantly, non-selective suppression of huntingtin was generally tolerated, however high dose AAV5-miHTT did induce astrogliosis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Finally, we also observed that potent reduction of wild type HTT (wtHTT) in Hu21 control mice was tolerated up to 7 months post-injection but may induce impairment of motor coordination and striatal atrophy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Taken together, our data suggests that in the context of HD, the therapeutic benefits of mHTT reduction may outweigh the potentially detrimental effects of wtHTT loss following non-selective HTT lowering.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Non-allele-selective lowering: unknown consequences in adults stated to trial participants
Extracellular vesicle-mediated spread of the therapeutic microRNA between cells
“Preclinical studies demonstrate the brain-wide spread of AAV5-miHTT following a single intrastriatal injection, which is partly mediated by neuronal transport.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Transfer of miHTT to recipient (HEK-293T, HeLa, and HD patient-derived neurons) cells was observed, which significantly reduced HTT mRNA levels.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In summary, we provide evidence that an engineered miRNA” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“is loaded into EVs, transported across extracellular space, and taken up by neighboring cells, and importantly, that miHTT is active in recipient cells downregulating HTT expression.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Two routes of spread from the injection site: axonal transport and vesicle transport
“(ii) The AAV is then transported to distant brain regions (e.g., the cortex) via axonal anterograde/retrograde transport.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“(iii) Because of its miR-451 scaffold, miHTT is actively and preferentially loaded into EVs, resulting in intercellular transport of miHTT, independently of neuronal connections, to adjacent cells.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Exon 1 huntingtin protein as a target: N-terminal fragments and aberrant splicing
“Various mechanisms lead to the production of N-terminal Huntingtin protein fragments, which are reportedly more toxic than the full-length protein.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Consistently accumulating evidence indicates that small N-terminal fragments containing extended polyQ tracts significantly contribute mHTT cellular mislocalization, aggregation and toxicity.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“AMT-130 is an AAV5-delivered miRNA which is administered through a one-time intrastriatal injection.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Target sequence present in both full-length and exon 1 huntingtin transcripts
“We have developed an engineered microRNA targeting the HTT exon 1 sequence (miHTT), delivered via adeno-associated virus serotype 5 (AAV5). The target sequence of miHTT is present in both FL HTT and HTT1a transcripts.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pharmacodynamics
Huntingtin lowering in the striatum and cortex of humanized mice at 7 months
“We show that intrastriatal administration of AAV5-miHTT results in potent and sustained HTT suppression for at least 7 months post-injection.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the striatum, we observed a dose-dependent reduction of wtHTT with low, medium and high dose treatments resulting in 42%, 62% and 87% suppression at 7 months post-injection, respectively” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Moreover, a dose-dependent reduction of wtHTT was also observed in the cortex with low, medium and high dose treatments resulting in 16%, 33% and 62% reduction at 7 months post-injection, respectively” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Greater lowering at the injection site than in the cortex
Huntingtin lowering and aggregate suppression in Q175 knock-in mice at 12 months
“A significant dose-dependent average reduction of mutant HTT protein of up to 39% in the striatum and up to 13% in the cortex of Q175 KI mice 12 months after intrastriatal injection of AAV5-miHTT was detected” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“AAV5-miHTT caused a dose-dependent and sustained HTT protein reduction with subsequent suppression of mutant HTT aggregate formation in the striatum and cortex.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Motor coordination and survival in R6/2 mice after a single administration
“AAV5-miHTT treatment showed a significant improvement in motor coordination on the rotarod by an increase in latency to fall of 22 s in the high-dose group, which is an increase of 56% compared with vehicle-treated R6/2 mice (one-way ANOVA, p = 0.0226; Figure 6B).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“One-time AAV5-miHTT administration resulted in a median survival improvement of over 4 weeks compared with untreated R6/2 HD mice.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Mutant huntingtin messenger RNA and protein lowering in transgenic minipigs
“Both human mutant huntingtin mRNA and protein were significantly reduced in all brain regions transduced by AAV5-miHTT.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Consistent with the vector DNA and miHTT expression in the cortex, we also detected a significant reduction of 42.7% (SD ±25.4%; p = 0.0066) more distal in the cortex.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This is the first demonstration of widespread human mutant huntingtin lowering in the large-animal model.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Mutant huntingtin protein lowering by brain region and in cerebrospinal fluid in minipigs at 6 and 12 months
“Expression of miHTT strongly correlated with vector DNA, with a corresponding reduction of mutant HTT (mHTT) protein of more than 75% in injected areas, and 30 to 50% lowering in distal regions.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“CSF miHTT expression was detected up to 12 months, with CSF mHTT protein lowering of 25 to 30% at 6 and 12 months after dosing.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Regional mutant huntingtin lowering reported by the sponsor at 12 months in minipigs
Huntingtin messenger RNA and protein lowering in patient-derived neurons
Reduction of exon 1 huntingtin messenger RNA and protein in two mouse models
“Intrastriatal administration of AAV5-miHTT resulted in dose-dependent expression of mature miHTT microRNA in cortical brain regions, accompanied by significant lowering of both FL HTT and HTT1a mRNA expression at 2 months postinjection.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Mutant HTT and HTTexon1 protein levels were also significantly reduced in the striatum and cortex of heterozygous zQ175 knock-in mice at 2 months after AAV5-miHTT treatment and in humanized Hu128/21 mice 7 months post-treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These data demonstrate that, in addition to FL HTT, AAV5-miHTT also effectively reduces the highly pathogenic HTTexon1 protein in HD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Neurochemical and volumetric markers in homozygous Q175FDN mice
“High dose AAV5-miHTT treatment partially rescued tNAA depletion (P = 0.0003) (Fig. 6A), and tNAA concentrations in high dose-treated animals were restored to near-wild-type levels.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“AAV5-miHTT partially rescues regional volume loss in brains of 6-month-old homozygous Q175FDN mice” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Finally, gene expression analysis by RNA sequencing revealed a distinct transcriptional phenotype associated with mutant HTT expression in the striatum that was partially rescued by high dose AAV5-miHTT.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Plasma neurofilament light chain unchanged by treatment in homozygous Q175FDN mice
“Plasma neurofilament light was elevated in homozygous Q175FDN mice (P < 0.0001) but was unchanged by AAV5-miHTT (Supplementary Tables 22 and 23), indicating that HTT lowering in the brain does not affect peripheral abundance of neurofilament light in this model.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“It is also possible that plasma neurofilament light may decrease with a longer treatment duration, and that our experimental timeline was too brief to capture the full effect of AAV5-miHTT therapy on this outcome measure.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Exploratory pharmacodynamic biomarkers in the U.S. study: mutant huntingtin and neurofilament light chain in cerebrospinal fluid
| Field | Quoted record |
|---|---|
| Exploratory outcome measure | “CSF Mutant Protein (fM)” |
| Exploratory outcome measure | “CSF/Serum Neurofilament Light Chain (pg/mL)” |
| Measure description of each | “Will be used as an exploratory biomarker to measure disease progression and responsiveness to AMT-130 treatment.” |
Durability marker: engineered microRNA in cerebrospinal fluid extracellular vesicles up to two years in non-human primates
“Quantifiable engineered microRNA levels enriched in extracellular vesicles were detected in the CSF up to two years after brain infusion.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Altogether, these results confirm the long-term expression of adeno-associated viral vector serotype 5-delivered microRNAs and support the use of extracellular vesicle-associated microRNAs as novel translational pharmacokinetic markers in ongoing clinical trials of gene therapies for neurodegenerative diseases.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pharmacokinetics
Vector biodistribution after MRI-guided convection-enhanced delivery in non-human primates and rats
“Widespread vector DNA and miHTT transgene distribution in the brain was found, particularly in areas associated with HD pathology.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Analysis of both NHP and rat brain regions showed high levels of vector DNA and miHTT expression that were sustained over 6 months and were widespread throughout the brain, thereby confirming high transduction of brain regions relevant for HD and subsequent expression of the transgene in those regions.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Dose-related transduction of the target structures was observed in NHP at 6 months following AAV5-miHTT administration.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Persistent expression and correlation of vector DNA with transgene expression
“AAV5-miHTT achieved persistent high-level expression of vector DNA and miHTT transgene.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Even though miHTT expression did not show a strong dose-dependent effect in the high dose, there was a strong correlation between brain vector DNA and miHTT transgene expression (r = 0.68, p < 0.0001) (Figure 3d).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Vector DNA in cerebrospinal fluid and blood immediately after administration
“The levels of vector DNA in the CSF in all AAV5-miHTT-treated NHP were approximately 1 × 1010 gc/mL at 1-h post injection.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These data show that after intrastriatal delivery of AAV5-miHTT the vector is shed into CSF and blood very rapidly, which indicated that initially the vector was able to spread systemically and was not limited to the CNS.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Shedding of vector DNA in body fluids and feces and its decline by three months
“One week after dosing, vector DNA was found in blood, plasma, feces, urine, nasal swabs and saliva.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These levels declined at 1 month after dosing and by 3 months after dosing the vector DNA levels were below the limit of detection for plasma, feces, urine and semen.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In feces, urine and semen vector DNA was found at day 7 and 1 months after dosing, but no vector was present after 3 months (data not shown).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Neutralizing antibodies to the vector capsid six months after dosing
Dose-dependent vector distribution in the transgenic minipig brain
“We detected widespread dose-dependent distribution of AAV5-miHTT throughout the tgHD minipig brain that correlated with the engineered microRNA expression.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Although both doses of AAV5-miHTT resulted in a local transduction and subsequently HTT mRNA and huntingtin protein lowering, the highest dose of AAV5-miHTT resulted in vector DNA and miHTT expression in the cortex, suggesting a dose-dependent viral transport.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Vector DNA distribution and persistence at 6 and 12 months in minipigs after striatal delivery
“rAAV5-miHTT (1.2 × 1013 vector genome (VG) copies per brain) was successfully administered into the striatum (bilaterally in caudate and putamen), using age-matched untreated animals as controls.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Widespread brain biodistribution of vector DNA was observed, with the highest concentration in target (striatal) regions, thalamus, and cortical regions.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Vector DNA presence and transgene expression were similar at 6 and 12 months after administration.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Extent of brain coverage reported by the sponsor in minipigs
Vector DNA in striatum, cortex, and cerebellum after striatal injection in mice
“AAV5 vector DNA was present in a dose-dependent pattern in (A) striatum (P < 0.0001) and (B) cortex (P = 0.0009), and detectable in high dose-treated animals in (C) cerebellum (P = 0.0326).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In striatum (the region of direct AAV5-miHTT injection), AAV5 vector DNA was detected in a dose-dependent pattern (P < 0.0001), with 9.6 × 105 and 4.3 × 107 AAV5 genome copies per μg total DNA measured in low and high dose-treated mice, respectively (Fig. 2A).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Distribution to the hippocampus and cortex and transduction of neurons, astrocytes, and microglia
“AAV5-GFP showed broad distribution at all time points evaluated and could clearly be observed in the striatum (site of injection), the hippocampus and deeper layers of the cortex at 7 months post-injection (Figure 2A).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We qualitatively observed co-localization of GFP with NeuN (Figure 2B), DARPP-32 (Figure 2C), GFAP (Figure 2D) and Iba1 (Figure 2E) demonstrating transduction of neurons, striatal medium spiny neurons, astrocytes and microglia, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Persistence in the brain and vector shedding as registry outcome measures
Contraindications/Warnings/Precautions/Adverse effects
Warnings and precautions
Not applicable.
Special populations
Pediatric use: UK paediatric investigation plan waiver granted in all age groups
Age range of the population studied in the European phase Ib/II study
Pregnancy and breastfeeding: excluded, with contraception required of participants
Hepatic and renal laboratory limits applied at screening
Juvenile Huntington's disease
No evidence found.
Dosing in hepatic impairment, renal impairment, or older adults
No evidence found.
Drug/Drug, drug/disease interactions
Effects of other drugs on Ifezuntirgene inilparvovec
Concomitant medications that could affect the ability to undergo the neurosurgical procedure
Coagulation and platelet thresholds required before administration
Prior experimental agents, gene therapy, and huntingtin-lowering strategies
Effects of Ifezuntirgene inilparvovec on other drugs
No evidence found.
Dosing and administration
Dosage
Dose supporting the marketing applications: 36-month data from high-dose participants
Single administration: one dose given during a neurosurgical visit
Infusion volume and concentration of the clinical dose
No evidence found.
Administration
Administration: single MRI-guided convection-enhanced stereotactic delivery into the caudate and putamen
Number of infusions per hemisphere
Burr holes and micro-catheter placement under general anesthesia
Procedure duration stated in the eligibility criteria of the European study
Delivery method described in a review of neurosurgical therapies for Huntington's disease
“In clinical trials, a current Phase 1/2 study funded by UniQure Biopharma includes patients with early manifestations of HD (ages 25–65 years) and uses bilateral striatal injection of AAV5-mHTT using an MRI-guided convection-enhanced delivery method and sham surgery for the randomized control arm” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Although technically possible, manual infusion does not offer the control and consistency of more advanced techniques” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“namely MRI-guided convection-based delivery using a pressure gradient generated by a pump.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Stereotactic neurosurgical techniques will be critical in optimizing therapeutic efficacy through safe, reproducible treatment delivery.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Convection-enhanced delivery: method and the role of real-time imaging
“CED, on the other hand, uses a pressure gradient generated by an automated pump to distribute high concentrations of macromolecules over significant volumes within the brain parenchyma by fluid convection, allowing for measurable, consistent and predictable infusion rates.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“One major challenge has been the lack of real-time visualisation of vector delivery, without which it is difficult to improve the distribution of vector during infusions.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This new paradigm allows visualisation of the accuracy and adequacy of viral vector delivery within target structures, enabling intertrial modifications in surgical approaches, cannula design, vector volumes and dosing.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cannula design and backflow during intraparenchymal infusion
“Features of the design of the infusion cannula for CED can profoundly impact successful delivery of gene therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Combined with increased infusion flow rates, these modifications resulted in greatly improved target coverage when evaluated in NHPs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Administration of the approved intraputaminal gene therapy eladocagene exuparvovec: setting and infusion parameters
| Field | Quoted record |
|---|---|
| Total recommended dose | “1.8x1011 vg (0.32 mL)” |
| Volume (dose) per infusion | “0.08 mL (0.45x1011 vg)” |
| Location of infusions | “2 in anterior putamen, 2 in posterior putamen” |
| Infusion rate at each target point | “0.003 mL/min” |
| Dose duration for infusion at each target point | “27 minutes” |
Access and distribution
Current access: clinical trials only; no expanded access
Commercial build-out: field medical, market access, and strategic account teams
Treatment centers: HDSA Centers of Excellence and stereotactic surgical infrastructure
Neurosurgical administration requirements
Manufacturing supply through Genezen
Specialty distribution, risk evaluation and mitigation strategy, and payer coverage
No evidence found.
Co-prescribed/Concomitant therapies
Background Huntington's disease medications: stable for 3 months before screening
Excluded prior and concurrent therapies
Immunosuppression regimen specified in the protocols
Immunosuppression at the discretion of the treating physician, October 2022
Perioperative immunosuppression and steroids given with administration, 2023
Prophylactic short-term steroid regimen, May 2025
Agents, doses, and duration of the immunosuppression regimen
No evidence found.
Effect of Ifezuntirgene inilparvovec on quality measures
AAN movement disorders quality measurement sets: conditions covered
Ifezuntirgene inilparvovec-specific effect on quality measures
No evidence found.
Product comparison
Tetrabenazine: indication, boxed warning monitoring, and individualized oral dosing
Deutetrabenazine: indication, boxed warning monitoring, and oral dosing
Valbenazine: indication, boxed warning monitoring, and oral dosing
Approved VMAT2 inhibitors: indirect tolerability comparison of deutetrabenazine and tetrabenazine
“Compared with tetrabenazine, deutetrabenazine was associated with a significantly lower risk of moderate to severe AEs and neuropsychiatric AEs including agitation, akathisia, depression, depression/agitated depression, drowsiness/somnolence, insomnia, and parkinsonism in both adjusted and unadjusted analyses (p < 0.05 for each).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Approved VMAT2 inhibitors: GRADE-based indirect comparison
Symptomatic antichoreic agents: open-label randomized comparison of tetrabenazine, tiapride, and olanzapine
“We conducted a pragmatic, randomized, open-label trial across 11 centers of the French-Speaking Huntington's Network, enrolling 179 patients with Huntington's disease.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Tetrabenazine was most frequently associated with mood disorders and sedation, while olanzapine caused occasional weight gain and mild increases in LDL and total cholesterol.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Route of administration compared with antisense oligonucleotides and gene therapy
HTT lowering targets in other trials: independent commentary
Registered trials of investigational disease-modifying therapies: mechanism, comparator, and design
Delivery routes under investigation: subcutaneous SRP-1005 as an alternative to intrathecal or neurosurgical administration
“SRP-1005 is designed to reduce HTT expression following subcutaneous administration through a transferrin receptor 1 -mediated delivery platform intended to facilitate central nervous system (CNS) penetration.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The programme is noteworthy for its systemic subcutaneous delivery approach, which, if successful, could provide an alternative to intrathecal or neurosurgical administration strategies currently being investigated for HTT-lowering therapies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Votoplam: oral splicing modifier, 24-month extension versus natural history
Votoplam: route and 12-week PIVOT-HD primary endpoint
“PTC518 (also known as votoplam), an orally administered huntingtin mRNA splice modulator.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The study met its primary endpoint, showing dose-dependent reductions in blood HTT protein levels at week 12, along with a favourable safety and tolerability profile across all dose levels and disease stages.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Votoplam: phase 3 INVEST-HD design
“INVEST-HD is a randomised, placebo-controlled, double-blind, phase III interventional study designed to evaluate whether votoplam slows disease progression in participants with early symptomatic HD compared with placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Votoplam, also referred to as HTT227 (and formerly known as PTC518), is an orally administered small-molecule HTT-lowering therapy now being developed by Novartis for HD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Participants are randomised in a 3:2 ratio to oral votoplam or placebo, with a variable double-blind treatment duration of up to 36 months, followed by a safety follow-up visit for participants not entering a separate open-label extension.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The estimated enrolment is 770 participants.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
SKY-0515 in relation to huntingtin-only lowering: independent trials review
“SKY-0515 is designed to reduce both HTT and PMS1 proteins, the latter implicated in somatic CAG repeat expansion, a mechanistic process increasingly recognised as a key driver of neuronal loss in HD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This important phase II/III clinical trial of SKY-0515 will assess whether HTT and PMS1 lowering can offer greater therapeutic benefit than HTT reduction alone in early-stage HD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
SKY-0515: twelve-month data compared with natural history and phase II/III FALCON-HD
“As previously featured in the October 2025 update, 13 Skyhawk Therapeutics has reported new interim data from the ongoing phase I/II study of SKY-0515.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Treated participants demonstrated positive mean changes from baseline in cUHDRS scores over 12 months, compared with an expected decline derived from propensity-weighted analyses of Enroll-HD and TRACK-HD natural-history datasets.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Skyhawk also announced completion of enrolment in the Australia and New Zealand component of the phase II/III FALCON-HD programme (004-ANZ), with 144 participants enrolled ahead of schedule, and expansion of the global FALCON-HD study (NCT07378644) 41 to eight countries.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
External natural-history comparisons across HTT-lowering trials
Tominersen: phase 3 GENERATION HD1 dosing discontinued
Tominersen: GENERATION HD1 design and primary end points
“in which 791 participants with manifest Huntington’s disease were randomly assigned in a 1:1:1 ratio to receive intrathecal tominersen, at a dose of 120 mg every 8 weeks or every 16 weeks, or placebo” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The primary end point was the change from baseline in the score on the composite Unified Huntington’s Disease Rating Scale (cUHDRS) or Total Functional Capacity (TFC) scale at week 101.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Biomarker end points included levels of mutant HTT in CSF, levels of neurofilament light protein (NfL) in CSF, and ventricular volume.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Tominersen: GENERATION HD1 ad hoc week 69 results with the every-16-week regimen
“In the every-16-week tominersen group, the mean changes from baseline in the scores on the cUHDRS and the TFC scale did not differ significantly from those in the placebo group (−0.16 points, adjusted P=0.84; and −0.04, adjusted P=1.00, respectively)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Nonetheless, these results must be interpreted with caution, given the ad hoc nature of the analysis.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Tominersen: GENERATION HD1 biomarkers, adverse events, and post hoc subgroup analyses
“The changes in mutant HTT levels in CSF were consistent with dose regimen–dependent decreases and concomitant increases in ventricular volume” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The absence of whole-brain volume loss in the context of ventricular expansion and the absence of a correlation between the change in CSF NfL levels and change in ventricular volume suggest that increases in ventricular volume do not reflect increased atrophy” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A transient increase was seen in CSF NfL levels in the every-8-week tominersen group at week 21; although neuroaxonal damage may be implicated, increased levels of leukocytes and total protein in CSF in some participants suggest an inflammatory component” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“More adverse events occurred in the participants in the every-8-week tominersen group than in those in the placebo group and the every-16-week tominersen group” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The results of post hoc analyses support the hypothesis that younger participants (who have less disease burden) may benefit from tominersen therapy” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“this hypothesis is currently being tested in a phase 2 dose-finding trial (GENERATION HD2; NCT05686551).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Tominersen: GENERATION HD2 discontinued, July 2026
“On 9th July 2026, Roche announced the discontinuation of the GENERATION HD2 (NCT05686551) 22 study of tominersen in people with prodromal and early Huntington's disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“GENERATION HD2 confirms that sustained lowering of mHTT in humans, even if it lowers wild-type as well, and does not target HTT exon 1, is associated with robust NfL lowering - often taken as indicating reduced rates of neuroaxonal damage - but that clinical benefits, if they are to emerge, may take longer than 16 months.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Tominersen: phase 2 GENERATION HD2 unblinding anticipated in late 2026, November 2025, superseded in July 2026
“GENERATION HD2 is a phase II, randomised, double-blind, placebo-controlled, dose-finding clinical trial comparing 60 mg tominersen, 100 mg tominersen and placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The clinical trial remains ongoing, and definitive conclusions regarding clinical benefit will only be possible once the data are unblinded and fully analysed. This is anticipated to be late 2026.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
RG6496: allele-selective intrathecal antisense oligonucleotide, POINT-HD terminated
“RG6496 is a selective ASO designed to lower mHTT protein while largely preserving expression of the wild-type protein.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“It is administered intrathecally and achieves allele selectivity by targeting a single nucleotide polymorphism (SNP) present on the expanded huntingtin gene (HTT) allele.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“POINT-HD was terminated following new findings from a longer-term non-clinical study indicating that RG6496 could not be administered chronically with repeated dosing.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pridopidine: phase 3 PROOF-HD and EMA opinion
“The primary and key secondary endpoints, change in total functional capacity (TFC) and composite Unified Huntington's Disease Rating Scale (cUHDRS) score at week 65, were not met in the overall population.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pridopidine: phase III PRECISE-HD in people not receiving antidopaminergic medications
“PRECISE-HD is a randomised, placebo-controlled, double-blind, phase III interventional study evaluating pridopidine 45 mg twice daily in adults with HD who have not used anti-dopaminergic medications for at least six months before screening.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The primary outcome measure is change from baseline to week 52 in cUHDRS score.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Approved AAV gene therapy: Kebilidi indication under accelerated approval
Kebilidi: accelerated approval on a single-arm study compared with an external natural history cohort
Kebilidi: confirmatory evidence required for continued approval
Direct head-to-head comparison of ifezuntirgene inilparvovec with an approved or investigational therapy
No evidence found.
Place of product in therapy
Disease description
Definition and etiology
Definition: progressive motor, cognitive, and psychiatric disorder
Etiology: expanded CAG repeat in HTT encoding a polyglutamine tract
“The disease is caused by an expanded CAG trinucleotide repeat (of variable length) in HTT, the gene that encodes the protein huntingtin.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Huntington's disease is an autosomal-dominant, progressive neurodegenerative disorder with a distinct phenotype, including chorea and dystonia, incoordination, cognitive decline, and behavioural difficulties.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
CAG repeat length thresholds
| Allele category | CAG repeat length |
|---|---|
| Normal alleles | “26 or fewer CAG repeats” |
| Intermediate alleles | “27 to 35 CAG repeats” |
| Reduced-penetrance HD-causing alleles | “36 to 39 CAG repeats” |
| Full-penetrance HD-causing alleles | “40 or more CAG repeats” |
Reduced penetrance of 36 to 39 CAG repeat alleles
“Variable penetrance for alleles carrying 36-39 repeats has been noted, but the disease appears fully penetrant when the repeat numbers are >40.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 18 of 7,315 individuals had ≥36 CAG, revealing that approximately 1 in 400 individuals from the general population have an expanded CAG repeat associated with HD (0.246%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The infrequent diagnosis of HD at this CAG length is likely due to low penetrance.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
CAG repeat length and age of onset
Juvenile Huntington's disease and anticipation
Epidemiology
Incidence of Huntington's disease
Global incidence: updated systematic review and meta-analysis, 2010 to 2022
“A total of 33 studies published between 2010 and 2022 were included. Pooled incidence was 0.48 cases per 100,000 person-years (95% CI, 0.33-0.63). Subgroup analysis by continent demonstrated a significantly higher incidence of HD in Europe and North America than in Asia.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Global incidence: systematic review and meta-analysis, 1985 to 2010
“Meta-analysis of data from four incidence studies revealed an incidence of 0.38 per 100,000 per year (95% confidence interval [CI]: 0.16, 0.94). Lower incidence was reported in the Asian studies (n = 2), compared to the studies performed in Europe, North America, and Australia (n = 6).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
United States incidence: commercial insurance claims, 2003 to 2016
“Using an insurance database of over 67 million enrollees, we retrospectively identified a cohort of 3,707 individuals diagnosed with Huntington’s disease between 2003–2016.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We estimated a cumulative age-adjusted HD frequency rate of 6.52 per 100,000 persons and a cumulative incidence rate of 1.22 per 100,000 person years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
United States incidence: Medicare beneficiaries aged 65 years or older
“In the Medicare population, 1,941 prevalent and 819 incident cases of HD were identified in 2017, corresponding to a prevalence proportion of 13.1 per 100,000 persons and incidence rate of 6.1 per 100,000 person-years.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
United Kingdom incidence: primary care records
“The data showed that the incidence of HD has remained constant between 1990 and 2010 with an overall rate of 7.2 (95% CI 6.5 to 7.9) per million person-years. The systematic review identified 14 independent estimates of incidence with substantial heterogeneity and consistently lower rates reported in studies from East Asia compared with those from Australia, North America and some--though not all--those from Europe.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There were 586 incident cases of HD from a total at‐risk population of 10,756,901 persons (corresponding to 80,048,926 PY) during the study period (Table 1). There was no evidence that incidence increased over time (β = 0.004, p = 0.4), with 16–44 newly diagnosed cases per year identified. In 2018, incidence of HD was 0.8 (0.5–1.19) per 100,000 PY.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Prevalence of Huntington's disease
Diagnosed prevalence by Shoulson-Fahn stage: share in stages 1 and 2
“The model estimates that in 2020, there were 66,787 individuals diagnosed with HD in the 8 included countries, of whom 62-63% were in Shoulson-Fahn stages 1 and 2 (with less severely limited functional capacity than those in stages 3-5).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Data on staging distribution at diagnosis, progression, and mortality were derived from Enroll-HD.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Sponsor statement: people with Huntington's disease in the United States, European Union, and United Kingdom
Sponsor estimate of the U.S. population treatable at launch
| U.S. population segment | Sponsor estimate |
|---|---|
| Initial treatable patients at launch (management estimate) | “~6,000” |
| Diagnosed HD | “~20,000 patients” |
| Symptomatic HD | “~40,000 patients” |
| Genetically identifiable HD | “~100,000 patients” |
Sponsor risk disclosure: addressable population may be smaller than projected
Global prevalence: updated systematic review and meta-analysis
Global prevalence: systematic review and meta-analysis, by region
“The worldwide service-based prevalence of HD, based on a meta-analysis (n = 13 studies), was 2.71 per 100,000 (95% CI: 1.55-4.72). Eleven studies were conducted in Europe, North American, and Australia, with an overall prevalence of 5.70 per 100,000 (95% CI: 4.42-7.35). Three studies were conducted in Asia, with an overall prevalence of 0.40 per 100,000 (95% CI: 0.26-0.61).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Geographic variation and prevalence trends
“The prevalence of HD varies more than tenfold between different geographical regions.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“There was evidence of an increasing prevalence of between 15 and 20% per decade in studies from Australia, North America and Western Europe.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
United States: symptomatic and at-risk population
United States: claims-based prevalence
“In the Medicare population, 1,941 prevalent and 819 incident cases of HD were identified in 2017, corresponding to a prevalence proportion of 13.1 per 100,000 persons and incidence rate of 6.1 per 100,000 person-years. In the Medicaid population, 353 prevalent cases of HD were identified in 2014, corresponding to a prevalence proportion of 15.2 per 100,000 persons.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
United Kingdom: primary care prevalence
“The estimated prevalence (expressed per 100 000 population) rose from 5.4 (95% CI 3.8 to 7.5) in 1990 to 12.3 (95% CI 11.2 to 13.5) in 2010.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Annual prevalence steadily increased throughout the study period, with prevalence estimates ranging from 4.3 cases (3.6–5.1) per 100,000 in 2000 to 9.2 cases (8.1–10.5) per 100,000 people in 2018 (β = 0.27, p < 0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Juvenile and pediatric Huntington's disease: proportion in Enroll-HD
Natural history, survival, and mortality
Enroll-HD: prospective observational natural history study, annual visits, and periodic data releases
“Enroll-HD is now operating worldwide in 21 countries at 159 clinical sites across four continents” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Europe, North America, Latin America, and Australasia” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“and has recruited almost 25,000 participants” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Central to the clinical research platform is the Enroll-HD study (NCT01574053), a prospective longitudinal observational study that collects natural history data in HD gene-expansion carriers (HDGECs) and non-HDGEC controls.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The Enroll-HD platform has been designed with the benefit of experience gained from several foundational HD studies” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“REGISTRY, PREDICT-HD, COHORT, and TRACK-HD/Track On-HD (12–16).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At their annual study visit, each participant is required to complete a core battery of assessments; extended and optional assessments are completed at the discretion of the PI and participant, respectively (Table 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“PDSs are prepared from the Enroll-HD study database every 1–2 years and include a large majority of the collected variables.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
TRACK-HD: 12-month changes in premanifest and early Huntington's disease
“TRACK-HD is a prospective observational study of Huntington's disease (HD) that examines disease progression in premanifest individuals carrying the mutant HTT gene and those with early stage disease.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“We report 12-month longitudinal changes, building on baseline findings.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Whole-brain atrophy rates were 0·20% (95% CI 0·05-0·34; p=0·0071) per year higher in preHD participants and 0·60% (0·44-0·76; p<0·0001) in early HD patients, and caudate atrophy rates were 1·37% (0·99-1·75; p<0·0001) per year higher in preHD and 2·86% (2·34-3·39; p<0·0001) in early HD.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Relative to controls, decline in cognition and quantitative motor function was detectable in both pre- and early HD, as was deterioration in oculomotor function in early HD.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Rate of functional decline on Total Functional Capacity: cohort of 960 participants followed prospectively
“The annual rate of functional decline was measured using the Total Functional Capacity Scale (TFC) and the Independence Scale (IS) in 960 patients with definite HD followed prospectively for a mean of 18.3 months.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The TFC score declined at a rate of 0.72 units/year (standard error [SE] 0.04) and the IS score declined at a rate of 4.52 units/year (SE 0.23).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Enroll-HD progression model: trajectories of functional, motor, and cognitive decline
“We included 8,071 Enroll-HD participants (mean baseline age: 51.4 years, 51.5% female) to develop a natural history progression model using baseline characteristics as predictive covariates.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Our analysis revealed that TFC and TMS are best characterized by logistic-like trajectories while cognitive scores (SDMT and SWR) display an exponential-like decline (Figure 1, B and C).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These results highlight the temporal differences in the rate of progression captured by different clinical end points and emphasize that individuals who exhibit rapid progression according to one clinical score may not necessarily exhibit fast progression according to another.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
GENERATION HD1 placebo arm compared with Enroll-HD natural history on Total Functional Capacity
“We observed that for the functional score (TFC), the progression during the trial aligns with the natural history progression, showing no sign of a relevant placebo response (Figure 4A).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“It is important to note that our analysis revealed that a placebo response initially leads to an improvement after baseline, but after accounting for this initial improvement, the rate of progression between the GENERATION HD1 placebo arm and Enroll-HD cohorts remained consistent.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Age at onset and prodromal phase
Prodromal change detected before diagnosis: PREDICT-HD
“1078 individuals with a CAG expansion were included in this analysis. Participants were followed up for a mean of 5·1 years (SD 3·3, range 0·0-12·0). 225 (21%) of these participants received a motor diagnosis of Huntington's disease during the study.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Disease stages: Huntington's Disease Integrated Staging System
“The HD-ISS characterises individuals for research purposes from birth, starting at Stage 0 (ie, individuals with the Huntington's disease genetic mutation without any detectable pathological change) by using a genetic definition of Huntington's disease. Huntington's disease progression is then marked by measurable indicators of underlying pathophysiology (Stage 1), a detectable clinical phenotype (Stage 2), and then decline in function (Stage 3).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Progression in premanifest and early disease: TRACK-HD
Survival after onset and age at death
“For these fully ascertained subjects, the range, mean, SD, and median of duration values were 0–46, 15.4, 6.8, and 15 years, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We found that, as with clinical onset, HD age at death is determined by expanded CAG-repeat length and has no contribution from the normal CAG allele. Surprisingly, disease duration is independent of the mutation's length.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Mortality relative to the general population: UK cohort
“The KM survival curve (Figure 1) shows a median survival time of 12.4 years (95% CI 10.6–15.2). Median age at death in individuals with HD and controls was 71 (IQR 59–79) and 81 (IQR 73–86) years, respectively. Individuals with HD were at 4.5 times greater risk of death than controls (hazard ratio 4.51, 95% CI 3.36–6.06, p < 0.001) after multivariable adjustment of baseline covariates (Figure S1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Age at death and causes of death: Norwegian national registries
“Mean age at death for individuals with HD was found to be 63.9 years (NCDR) and 61.7 years (CRD), compared to a mean of 76.9 years in the general population (NCDR).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In 73.5% of individuals with HD, the underlying cause of death was HD, followed by cardiovascular diseases, cancer and respiratory diseases. The most common immediate cause of death was respiratory diseases (44.2%). Suicide was a more common cause of death in the population with HD (2.3%) compared to the general population (1.3%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Causes of death: aspiration pneumonia
“Two hundred twenty four charts of deceased HD patients were reviewed, of which 216 (111/104 male/female, one unknown) had records available, 147 listed a cause of death (Table 1), which was pneumonia in 81 (55%) cases.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The conclusion is that the majority (86.8%) of our HD patients where the cause of death could be identified died from aspiration pneumonia.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Suicide and suicidal ideation
“Incidence of suicidal ideation, suicide attempt, and suicide are higher among those with HD relative to the non-HD population.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“At baseline, 169 (8.0%) mutation carriers endorsed suicidal ideation.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The 4-year cumulative incidence of suicidal ideation was 9.9%.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Juvenile Huntington's disease: progression and survival
“Disease progression of JHD is faster compared to AOHD and the disease duration is shorter, particularly in case of higher CAG repeat lengths.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Disease progression was more rapid in juvenile Huntington's disease (n=14) than in adult-onset Huntington's disease (n=52; generalised estimating equation model, p=0·0003). Of 121 deceased patients, median survival was shorter in the juvenile Huntington's disease (n=17) cohort than in adult-onset Huntington's disease (n=104) cohort (hazard ratio 2·18 [95% CI 1·08-4·40]; p=0·002).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Pathophysiology
Mutant huntingtin: toxic gain of function
“In mutation carriers, huntingtin is produced with abnormally long polyglutamine sequences that confer toxic gains of function and predispose the protein to fragmentation, resulting in neuronal dysfunction and death.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“At the cellular level mutant huntingtin results in neuronal dysfunction and death through a number of mechanisms, including disruption of proteostasis, transcription and mitochondrial function and direct toxicity of the mutant protein. Early macroscopic changes are seen in the striatum with involvement of the cortex as the disease progresses.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Striatal degeneration: neuropathological grading
“The earliest changes were seen in the medial paraventricular portions of the caudate nucleus (CN), in the tail of the CN, and in the dorsal part of the putamen. Counts of neurons in the CN reveal that 50% are lost in grade 1 and that 95% are lost in grade 4” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Genetic modifiers of onset: DNA repair genes identified by GWAS
“Association at MLH1 and pathway analysis of the full GWA results support a role for DNA handling and repair mechanisms in altering the course of HD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The timing of onset shows no significant association with HTT cis-eQTLs but is influenced, sometimes in a sex-specific manner, by polymorphic variation at multiple DNA maintenance genes, suggesting that the special onset-determining property of the uninterrupted CAG repeat is a propensity for length instability that leads to its somatic expansion.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Four genes at 3 loci were significant after Bonferroni correction: FAN1 (p = 1.9E-22), MSH3 (1.9E-8), PMS1 (6.1E-7), and ASNSD1 (5.3E-6) with later onset associated with increased FAN1, PMS1, and ASNSD1 expression and decreased MSH3 expression.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Genetic modifiers of progression: MSH3 and PMS1
“The lead single nucleotide polymorphism (SNP) in TRACK-HD (rs557874766) was genome-wide significant in the meta-analysis” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“encodes an aminoacid change (Pro67Ala) in MSH3” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Knockout of Msh3 reduces somatic expansion in Huntington's disease mouse models, suggesting this mechanism as an area for future therapeutic investigation.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Genome-wide association studies (GWASs) of Huntington disease (HD) have identified six DNA maintenance gene loci (among others) as modifiers and implicated a two step-mechanism of pathogenesis: somatic instability of the causative HTT CAG repeat with subsequent triggering of neuronal damage.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In addition, we identified additional modifier effects at the PMS1 and PMS2 loci and implicated a potential second locus on chromosome 7.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Somatic CAG repeat expansion in striatal projection neurons
“We found that the HTT CAG repeat expands somatically from 40-45 to 100-500+ CAGs in SPNs. Somatic expansion from 40 to 150 CAGs had no apparent cell-autonomous effect, but SPNs with 150-500+ CAGs lost positive and then negative features of neuronal identity, de-repressed senescence/apoptosis genes, and were lost.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We conclude that in HD, at any one time, most neurons have an innocuous but unstable HTT gene, and that HD pathogenesis is a DNA process for almost all of a neuron’s life.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
PMS1 as a modifier of somatic CAG repeat expansion
Multiple pathogenic mechanisms
“Mutant HTT (mHTT) disrupts transcription, interferes with immune and mitochondrial function, and is aberrantly modified post-translationally. Evidence suggests that the mHTT RNA is toxic, and at the DNA level, somatic CAG repeat expansion in vulnerable cells influences the disease course.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Diagnosis
Establishing the diagnosis: clinical findings and molecular genetic testing
“The diagnosis is usually confirmed through identification of an increased CAG repeat length in the huntingtin gene in a patient with clinical features of the condition. Though diagnosis is usually straightforward, unusual presentations can occur, and it can be difficult to know when someone has transitioned from being an asymptomatic carrier into the disease state.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Clinical motor diagnosis: diagnostic confidence level
“Huntington's disease (HD) is currently diagnosed based on the presence of motor signs indicating 99% "diagnostic confidence" for HD. Recent advances in the understanding of HD natural history and neurobiology indicate that disease-related brain changes begin at least 12 to 15 years before the formal diagnosis based on motor onset.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“with the gene mutation for Huntington's disease but without a motor diagnosis (a rating below 4 on the diagnostic confidence level from the 15-item motor assessment of the Unified Huntington's Disease Rating Scale)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Staging: Huntington's Disease Integrated Staging System
“The Huntington's Disease Integrated Staging System (HD-ISS) comprises a biological research definition and evidence-based staging centred on biological, clinical, and functional assessments.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“If there are signs of neurodegeneration, evidenced by atrophy of the caudate or putamen, individuals are assigned to stage 1. If disease signs are measurable by the TMS or Symbol Digit Modalities Test (SDMT), they are classified as stage 2. Finally, if there is an impact on daily functioning as assessed by the Total Functional Capacity (TFC) or the Independence Scale, individuals are assigned to stage 3.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Clinical motor diagnosis, or a Diagnostic Confidence Level (DCL) of 4, corresponds to the latter part of HD-ISS stage 2.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Predictive genetic testing in at-risk individuals
Biomarkers: plasma neurofilament light protein
“Mean concentrations of NfL in plasma at baseline were significantly higher in HTT mutation carriers than in controls (3·63 [SD 0·54] log pg/mL vs 2·68 [0·52] log pg/mL, p<0·0001) and the difference increased from one disease stage to the next.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In 104 individuals with premanifest Huntington's disease, NfL concentration in plasma at baseline was associated with subsequent clinical onset during the 3-year follow-up period (hazard ratio 3·29 per log pg/mL, 95% CI 1·48-7·34, p=0·0036).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Clinical presentation - signs and symptoms
Motor symptoms: dystonia, bradykinesia, rigidity, and oculomotor disturbance
Motor symptoms: gait disturbance and falls
Cognitive symptoms: executive dysfunction and progressive decline
“Chorea and other aspects of the movement disorder are the most visible aspect of the disease. However, non-motor features have greatest affect on functional independence and quality of life, so require recognition and management.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Psychiatric symptoms: depression, irritability, apathy, and anxiety
“Ninety eight per cent of the patients exhibited neuropsychiatric symptoms, the most prevalent being dysphoria, agitation, irritability, apathy, and anxiety.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Other symptoms: weight loss
Other symptoms: sleep and circadian disturbance
Juvenile Huntington's disease: presentation
Long-term morbidity
Loss of functional independence
Neuropsychiatric symptoms and functional capacity: systematic review
Falls and injury
“Twenty-seven patients (60%) reported two or more falls in the previous year and were classified as fallers. During prospective follow-up 40% reported at least one fall. A high proportion of falls (72.5%) caused minor injuries.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Three months before death, anxiety (11% vs. 5%, 2.11, 0.7–5.6, p = 0.15), depression (28% vs. 6%, 4.28, 1.72–8.67, p < 0.001), falls (25% vs. 8%, 2.5, 1.18–4.73, p < 0.05), insomnia (25% vs. 4%, 8.82, 3.62–20.19, p < 0.001) and fractures/breaks/sprains (20% vs. 10%, 1.83, 0.85–3.35, p = 0.09) were more prevalent in HD cases.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pneumonia, weight loss, dementia, and other comorbidities after diagnosis
“Incidence rates of the following were statistically higher in individuals with HD than controls: psychotic disorders, psychosis, insomnia, dementia, depression, pneumonia, weight loss and falls.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The most commonly mentioned causes of death (any mention) were HD (78.3%), bronchopneumonia (unspecified) (15.9%), pneumonitis due to food and vomiting (10.4%), unspecified dementia (6.6%) and sepsis (6.6%) (Table S8).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Institutionalization: skilled nursing facility placement
“Among 4,809 subjects enrolled, 3,070 had clinically definite HD. Of these, 228 (7.4%) resided in SNF. The SNF residents' average age was 52 years, average disease duration was 8.6 years, and they were predominantly women (63%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In the Cox model, bradykinesia (HR 1.965, 95% CI 1.083 to 3.564), impaired gait (HR 3.004, 95% CI 1.353 to 6.668), and impaired tandem walking (HR 2.546, 95% CI 1.460 to 4.439) were predictive of SNF placement.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Juvenile Huntington's disease: long-term motor morbidity and seizures
“Compared with the LE subgroup, development delay (0 [0%] in the LE subgroup vs nine [90%] in the HE subgroup; p<0·0001), severe gait impairment (nine [35%] in the LE subgroup vs nine [90%] in the HE subgroup; p=0·0072), and seizures (three [11%] in the LE subgroup vs eight [80%] in the HE subgroup; p<0·0001) prevailed over time in the HE subgroup.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Burden of Huntington's disease
Humanistic burden and health-related quality of life
HDBOI study: EQ-5D-5L, SF-6D, and H-QoL-I scores by disease stage
“A total of 2,094 PwHD were enrolled with completed eCRFs (100%) and PPIE-P forms (n = 482, 23%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The mean EQ-5D-5L (n = 336) utility score was 0.59 (SD, 0.27), with the highest mean utility scores [SD] in ES (0.72 [0.22]) followed by MS (0.62 [0.18]) and AS (0.37 [0.30]), p < 0.001.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The mean SF-6D score (n = 482) was 0.57 (SD, 0.10), with mean values decreasing with advanced disease (ES, 0.61; MS, 0.56; AS, 0.50, p < 0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“H-QoL-I mean scores (n = 482) also worsened with more advanced disease, from 0.58 for ES to 0.49 for MS and 0.37 for AS, p < 0.001.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Overall proxy respondents reported on average worse outcomes than PwHD (self-reported) across all outcomes and disease stages suggesting a possible unawareness of deficits by PwHD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Health state utility values: systematic literature review
“Of 383 articles screened, 16 articles reported utility values estimated in 11 distinct studies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The EQ-5D index range was 0.89 - 0.72 for mild/prodromal HD and 0.71 - 0.37 for severe/late-stage disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This study uncovered high variability in published utility estimates, indicating substantial uncertainty in existing data.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Health state utility values: EHDN REGISTRY SF-6D analysis
“11,328 questionnaires were completed by 5560 respondents with HD in 12 European countries.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Women generally had lower HSUVs than men, and HSUVs were consistently lower than population norms for those with HD in the UK, and dropped with increasing disease severity.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“with TFC score, Behavioural score, and male gender significant predictors of SF-6D values (p < 0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Stage-specific utility values applied in a U.S. cost-effectiveness model
“Health utilities for SoC were derived from the Hawton et al. study” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“that used SF-6D preference-based measures to estimate stage-specific utilities for HD.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Norway cross-sectional study: EQ-5D-3L values by disease phase
“Mean HRQoL values declined across disease phases for the 84 participants; early phase (n = 34): mean = 0.84 (SD = 0.13), middle phase (n = 19): mean = 0.74 (SD = 0.10) and advanced phase (n = 31): mean = 0.65 (SD = 0.5).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Spain: H-QoL-I and EQ-5D-3L
“Fifty-five patients and an equal number of caregivers participated.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The usual activities and anxiety/depression were the most severely altered dimensions according to the EQ-5D-3L results.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Increase of disease severity resulted in lower patient QoL.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Chorea health states: time trade-off utility values in the general population
“Mean ± SD TTO-derived utility values were 0.07 ± 0.52, 0.26 ± 0.50, 0.48 ± 0.47, and 0.64 ± 0.41 for severe, moderate/severe, moderate/mild, and mild chorea severity, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Respondents were willing to give up 3.6, 5.2, 7.4, and 9.3 years during a 10-year life span to avoid living with mild, mild/moderate, moderate/severe, and severe chorea, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
HDQLIFE: development of a disease-specific HRQoL measurement system
“Existing item banks and new item pools were field tested in 536 individuals with prodromal, early-, or late-stage HD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“HDQLIFE encompasses both validated Neuro-QoL/PROMIS measures, as well as five new scales in order to provide a comprehensive assessment of HRQOL in HD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
HDQLIFE physical function measures: reliability and validity
“A total of 510 individuals with Huntington's disease completed 2 Quality of Life in Neurological Disorders (Lower Extremity Function and Upper Extremity Function) and 3 Huntington's Disease Health-Related Quality of Life (Chorea, Speech Difficulties, and Swallowing Difficulties) measures.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Reliabilities for the new patient reported physical functioning measures were excellent (all Cronbach's α > .92).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Chorea and HRQoL: U.S. online survey using HDQLIFE
“A total of 115 participants (n = 35 caregivers; n = 80 individuals with HD) were included in this study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among those experiencing chorea (n = 83, 74% of respondents), 66% indicated it was 'Very Important' to manage chorea; however, only 47% agreed that their current medication regimen helped manage their movements.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“significantly higher Anxiety (P = 0.0423) and stigma (P < 0.0001) scores were observed among respondents with high chorea than in those with low chorea.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Determinants of HRQoL: functional capacity and depressive mood
“Multiple regression analyses showed that functional capacity and depressive mood were significantly associated with HrQOL, in that greater impairments in HrQOL were associated with higher levels of depressive mood and lower functional capacity.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Motor symptoms and cognitive function were not found to be as closely linked with HrQOL.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Psychiatric burden: suicidal ideation and sleep disturbance in the HDBOI study
“PwHD reported current (13%, n = 272) or previous (28%, n = 575) suicidal ideation, which was more common with advanced HD (ES, 11%; MS, 14%; AS, 15%; p < 0.05).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of 482 questionnaire respondents, 91% (n = 437) reported difficulty sleeping, which was more common with AS HD (p < 0.05; [p = 0.000]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Psychiatric burden: suicidal ideation measured with HDQLIFE Concern with Death and Dying items
“We examined 496 participants with premanifest or manifest HD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Our sample had a significantly higher occurrence of suicidal ideation (19.76%) and suicidal plans (2.1%) than the general population (p < 0.0001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
U.S. survey: individuals with HD and care partners compared with Parkinson's disease and the general population
“IHD had greater comorbid anxiety (IHD = 51.2%, IPD = 28.8%, GP = 2.0%), and HD-CP had greater comorbid anxiety (HD-CP = 52.5%, PD-CP = 28.6%, GP-CP = 19.6%) and depression (HD-CP = 65.0%, PD-CP = 29.9%, GP-CP = 19.6%), relative to other cohorts (p < 0.05).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Respective of their GP cohorts, IHD exhibited lower HRQoL (EQ-5D: 0.66 ± 0.21 vs. 0.81 ± 0.17) and greater depression (PHQ-9: 11.59 ± 7.20 vs. 5.85 ± 6.71), whereas HD-CP exhibited greater depression only (PHQ-9: 6.84 ± 6.38 vs. 4.15 ± 5.58) (p < 0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Canada: HRQoL of individuals with HD and care partner strain
“A total of 62 adult individuals with HD (or their proxies) and 48 care partners met defined eligibility criteria.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For individuals with HD, the greatest HRQoL burden (i.e., lowest score) was for the SF-36v1 Role -Physical scale (46.8 [42.9]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among care partners, 55.3% experienced high strain, as indicated by the CSI.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Caregiver burden: prospective longitudinal study of patient and caregiver pairs
“105 caregiver/patient pairs were included in the analysis.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Of the two clusters of patients with advanced disease, cluster A was characterized by high levels of irritability and obsessive-compulsive behaviors, with high and increasing burden (N = 30; 29%), cluster B, the more apathetic group, with low and decreasing burden (N = 22; 21%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Caregiver burden: South Korea prospective cohort
“Sixty-five patients with HD and 45 caregivers were enrolled in this cohort study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A higher caregiver burden was associated with a more severe Shoulson-Fahn stage (p = 0.038) of the patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Caregiver burden: systematic review
“Twelve studies were included in the review involving 569 caregivers of patients with HD.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Neuropsychiatric symptoms and the hereditary nature of the disease have been identified as important correlates of caregiver strain.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Patient and caregiver experience: ICER stakeholder input
Multigenerational burden: qualitative study across six European countries
“Cognitive and psychiatric symptoms were particularly burdensome, driving declines in quality of life (QoL) and emotional well-being.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Caregivers reported extensive physical, financial, and psychological strain, with many assuming care responsibilities from a young age or eventually caring for multiple relatives.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Economic burden and healthcare resource utilization
U.S. commercial and Medicaid claims (2002 to 2009): direct medical costs by stage
“Among 1272 HD patients, the mean age was similar in commercial (752 patients) and Medicaid (520 patients) populations” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The mean total annualized cost per patient increased by stage (commercial: $4947 (SD = $6040)-$22,582 (SD = $39,028); Medicaid: $3257 (SD = $5670)-$37,495 (SD = $27,111).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The vast majority (73.8%) of Medicaid Late stage patients received nursing home care and the majority (54.6%) of Medicaid Late stage costs were associated with nursing home care.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Key limitations include the classification of patients into a single stage, as well as a lack of visibility into full long-term care/nursing home-related costs for commercial patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
U.S. Medicare fee-for-service claims (2013 to 2017): costs versus matched beneficiaries and by stage
“We identified 3,688 matched pairs of beneficiaries with and without HD.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Mean [SD] annual total healthcare costs were higher for HD beneficiaries than beneficiaries without HD ($41,631 [57,393] vs. $17,222 [31,218], p < .001) and were primarily driven by outpatient pharmacy costs ($19,182 [45,469] vs. $4,318 [11,553], p < .001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In the stratified analysis, total healthcare costs were highest among beneficiaries with late-stage HD (mean [SD] cost: $20,475 [$41,122] for early-stage vs. $29,733 [$44,977] for middle-stage vs. $56,657 [$64,185] for late-stage; p < .001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
U.S. Medicaid Analytic eXtract (2010 to 2014): costs versus matched beneficiaries and by stage
“A total of 1,785 beneficiaries without HD were matched to 595 beneficiaries with HD (139 early-, 78 middle-, and 378 late-stage).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The mean (SD) annual total costs were higher for beneficiaries with HD than beneficiaries without HD ($73,087 [$75,140] vs. $26,834 [$47,659], p <.001) and driven by inpatient costs ($45,190 [$48,185] vs. $13,808 [$39,596], p <.001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Total healthcare costs were highest among beneficiaries with late-stage HD (mean [SD] cost: $22,797 [$31,683] for early-stage HD vs. $55,294 [$129,290] for middle-stage HD vs. $95,251 [$60,197] for late-stage HD; p <.001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
U.S. MarketScan commercial, Medicaid, and Medicare Supplemental claims (2009 to 2018): HRU and costs per patient per month by stage
“A total of 2,669 individuals with HD were identified. Of these, 1,432 (53.7%), 689 (25.8%), and 548 (20.5%) had early-, middle-, and late-stage HD at baseline, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Mean total all-cause healthcare cost PPPM for individuals with HD was $2,889, and it was significantly higher in middle-stage individuals, at $7,988, compared with early- and late-stage individuals, at $3,726 and $5,125, respectively; p <0.0001.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Our evaluations didn't include the indirect costs of HD, which may be substantial as HD typically affects people at their peak earning potential.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
U.S. MarketScan claims: costs versus propensity-matched controls without HD
“A total of 2,473 individuals with HD and 9,522 matched non-HD controls were identified.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Mean total costs (2018 USD PPPM) for the HD cohort ($2,260 [SD = $4,682]) were twice the total costs in the non-HD cohort ($1,056 [SD = $3,078]) (P < 0.0001) and were highest across all disease stages.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
U.S. MarketScan claims: late-onset versus adult-onset HD
“In total, 763 individuals with LoHD and 1,073 individuals with AoHD were matched with 3,762 non-HD controls.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In the 12 months post-index, mean total costs for the LoHD cohort ($29,055) were significantly higher than for non-HD controls (≥60 years old: $17,286; 21-59 years old: $12,688; p <.001) and similar to total costs in the AoHD cohort ($31,701; p =.47).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
U.S. MarketScan claims (2017 to 2021): HD-related costs by diagnosing provider type
“Three hundred and forty eligible patients had a mean age at diagnosis of 49 years.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“HD-related mean costs totaled $2,489 ($1,179 inpatient and $1,310 outpatient).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Patients diagnosed by neurologists had significantly lower HD-related total non-medication costs vs. those diagnosed by PCPs (-$2,256; p < 0.05).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Systematic review of cost-of-illness studies: annual costs by stage and cost type (2023 U.S. dollars)
Systematic review of cost-of-illness studies: synthesis
“Only five studies were included for extraction and synthesis including three from the USA, one from the United Kingdom (UK), and one from Peru.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Outpatient costs were approximately 2.5 times greater than inpatient costs for early and middle stages of HD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among all the costs associated with HD, annual caregiver cost emerges as the most significant costs in the economic burden of HD, ranging from a minimum of $6041 for early stage to a maximum of $133,200 for late-stage HD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Global systematic review: annual costs by region (2024 U.S. dollars)
“Out of the initial 608 de-duplicated articles, 19 full-text articles were included.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Annual costs in 2024 USD ranged significantly by region: Americas ($2542-$90,515), Europe ($40,000-$215,020), Asia ($1915-$7132), and Oceania ($3678-$8721).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
HDBOI study (France, Germany, Italy, Spain, United Kingdom, United States): direct, nondirect, and indirect costs
“HDBOI cost estimates were €12,663 (n = 2094) for direct medical costs, €2984 (n = 359) for nondirect medical costs, and €47,576 (n = 436) for indirect costs.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Costs are higher in patients who are at later stages of disease; for example, direct medical costs estimates were €9220 (n = 846), €11,885 (n = 701), and €18,985 (n = 547) for ES, MS, and AS, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Costs show large variations between patients and countries.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
HDBOI study: design, participants, and costing methods
“The HDBOI study is a noninterventional, retrospective, cross-sectional, international burden of illness study of people with diagnosed HD in France, Germany, Italy, Spain, the UK, and the USA.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 2094 PwHD were enrolled in the HDBOI study, 40% of whom (n = 846) were classified as ES, 34% as MS (n = 701), and 26% as AS (n = 547; Table 1).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Information regarding HD-related health care resource use used to compute direct medical costs was available for all 2094 PwHD. Information on direct nonmedical costs was available for 359 PwHD and indirect costs for 436 PwHD.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Costs are reported in 2020 euros for all outcomes” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“To minimize underestimation of costs due to potentially reduced care interactions during the coronavirus disease 2019 (COVID-19) pandemic, health care resource use (used to compute direct medical costs) was extracted for a set time period before the pandemic (March 2019 through March 2020).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“For actively employed PwHD and caregivers, productivity loss was quantified as the number of days missed from work due to HD in the past 3 months multiplied by the country average salary per day.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“For those unable to work due to HD, an opportunity cost was assigned based on 1 year of average salary per country.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
HDBOI study: mean annual costs by disease stage (2020 euros)
HDBOI study: cost drivers and mean annual cost components by stage (2020 euros)
“Inpatient hospitalizations and residential care were the primary drivers of direct medical costs” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Total costs (sum of direct medical, nonmedical, and indirect costs), available for a subsample of 307 PwHD (patients with a completed eCRF, PPIE-P, and PPIE-C), were driven primarily by indirect costs, which accounted for 84%, 80%, and 66% of ES, MS, and AS total costs, respectively (Appendix Table A2).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
HDBOI study: mean annual costs by country (2020 euros)
“Direct nonmedical costs were highest in Italy (€3977) and the UK, and indirect costs were highest in the USA (€74,228 [$90,187]), the UK, and Italy” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The HDBOI study reported direct medical costs of €27,743 in the USA and a substantial indirect cost burden of €74,228 from lost work productivity.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
HDBOI study: stated limitations of the cost estimates
“Because recruitment was driven through clinician office visits, AS patients may have been underrepresented if they were admitted to long-term residential or nursing care homes.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Cost estimates for AS PwHD may have been underestimated due to the small sample of patients with advanced disease and subsequent subgroup analyses.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“For Germany, direct medical costs may have been underestimated, as only copayments were publicly available, which do not reflect the true cost of the service delivered.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
United Kingdom EHDN REGISTRY: annual societal costs by TFC stage (2013 pounds)
United Kingdom EHDN REGISTRY: cost drivers
“The mean annual cost per person with HD was £21 605. The largest proportion of this cost (65%) was due to informal care (£14 085).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This equates to £195 million per year in the UK.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Norway: six-month healthcare and societal costs
“Total six-month healthcare costs and total societal costs were € 18,538 and € 66,789 respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Main six-month cost components for the three disease phases were informal care costs (€ 30,605) accounting for approximately half the total societal costs, and costs due to production loss (€ 18,907) being slightly higher than the total healthcare costs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Long-term care in advanced HD: North American systematic literature review
Hospice and palliative care utilization in the United States
“Of the 164,032 patients admitted to these hospices, 101 (0.06%) had a primary diagnosis of HD.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Patients had a median length of stay in hospice of 42 days, which was significantly longer than that of other hospice patients in the sample (17 days), P < 0.001.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Predictors of health care utilization: Enroll-HD Northern America
“Visits from 1,631 participants in the Northern America region from the Enroll-HD study were included in this study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Clinical factors, such as psychiatric symptoms, functional ability, and comorbidities, were associated with use of multiple types of health care services.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Employment loss by disease stage: Enroll-HD
Employment and work productivity: HDBOI participants
Employment: chorea and cognitive decline
“Patients with chorea were less likely to be employed full-time (16.7% vs 25.7%; P<0.04) and more likely to be on long-term sick leave (17.4% vs 5.0%; P<0.01).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For every year delay in cognitive symptom onset, there was a 0.806 year increase in age at leaving work (SE = 0.030, p < 0.001, adj-R2 = 0.628).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Twenty-three studies were identified and showed that while employment and working capacity in HD are negatively influenced by cognitive decline and motor impairments, apathy already plays a role in the prodromal stage.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Canada (Alberta): direct healthcare costs under a universal public system
“The mean total all-cause direct healthcare costs were $23,211 [$38,599] per person-year, with hospitalizations accounting for 57.8% of all-cause costs.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Costs were higher among individuals with a long-term care stay, a proxy for disease severity.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Other countries: Israel, China, Peru, Brazil, and Germany
“Total healthcare and medication costs per patient (US dollars) were significantly higher for PwHD than controls ($7,343 vs. $3,625; P < 0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The average annual direct medical cost, direct non-medical cost, and indirect cost were 3,265.65, 805.82, and 801.97 Euros, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The average annual cost of HD reached USD 8120 per patient in 2015.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The mean cost of HD increased with the degree of patient dependency: from USD 6572 for Barthel 4 & 5 (slight dependency and total independency, respectively) to USD 23,251 for Barthel 1 (total dependency).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Significant economic impacts were observed, with average annual direct medical costs of $4686.82 per HD patient.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Thirty-three out of 34 HD patients were unemployed or retired, and 16 relied on government benefits, reflecting broader socioeconomic implications.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Physical therapy was the most often used medical aid in HD patients (46.4%). Nursing services and speech therapy were used by 27.9 and 22.7% of HD patients, respectively, whereas use of psychotherapy was rare (3.2%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Economic impact of Huntington's disease on families
Informal care and caregiver productivity costs: HDBOI study (2020 euros)
“Indirect costs for informal care were calculated as the total number of hours per week of informal care multiplied by the number of weeks per year. Total number of hours per year was multiplied by the country average salary per hour.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Caregiver state support accounted for 58%–75% of all direct nonmedical costs. Indirect costs were driven by lost productivity for PwHD (34%–42%) and costs of informal care requirements (40%–42%; Appendix Table A2).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
| Cost component | Early stage, mean (SD) and n | Mid stage, mean (SD) and n | Advanced stage, mean (SD) and n |
|---|---|---|---|
| Informal care | “€27,760 (€37,790) n = 121”View highlighted excerpt for this quote | “€30,243 (€37,046) n = 120”View highlighted excerpt for this quote | “€37,758 (€45,515) n = 83”View highlighted excerpt for this quote |
| Lost productivity, caregiver | “€18,225 (€19,864) n = 33”View highlighted excerpt for this quote | “€12,988 (€15,621) n = 46”View highlighted excerpt for this quote | “€17,280 (€19,266) n = 49”View highlighted excerpt for this quote |
| State support, caregiver | “€5134 (€5834) n = 22”View highlighted excerpt for this quote | “€5897 (€5098) n = 36”View highlighted excerpt for this quote | “€4778 (€3359) n = 43”View highlighted excerpt for this quote |
Informal caregiver time and objective burden: France
“We included 80 ICs (mean [SD] age 57 [12.9] years, 60% women) in charge of 80 individuals with early to advanced stage HD” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The mean hours of informal care time was high: 7.3 (7.9) h/day (range 0-24); the mean professional home care was 2.8 (2.8) h/day (range 0.1-12.3).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The burden was partially related to the multiplex caregiving status (19%). Protective factors lowering the IC burden included the absence of financial hardship (57%), a strong social network (16%) and keeping active on the job market outside home (46%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Caregiver employment and work productivity: HDBOI caregivers
Caregivers of people with advanced HD in North America: systematic literature review
| Caregiver outcome | Quoted value |
|---|---|
| Mean time spent as primary carer (years) | “10.2 years” |
| Total hours of formal care per week | “43 hours” |
| Total hours of informal care per week | “41 hours” |
| Prevented career progression | “51%” |
| Prevented from working more hours | “70%” |
| Overall work productivity loss | “54%” |
Informal care as a share of societal cost: United Kingdom and Norway
“Informal care was the largest driver of costs across all stages of HD; thus there is a need to also consider the needs of carers when planning services for people with HD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Our results highlight the crucial role the informal caregivers play in the care provided to HD patients in all disease phases. Future research should focus on the estimation of productivity loss among informal caregivers.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Out-of-pocket financing by families: Peru
“Direct non-healthcare costs represented 78.3% of total cost, indirect costs 14.4% and direct healthcare costs the remaining 7.3%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Direct costs were primarily financed by patients and their families.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Juvenile-onset HD: costs to the NHS and to families (England and Wales, 2020 pounds)
“The overall mean JoHD cost to the NHS per year (2020) was £126,966 which varied according to disease severity, costing just under £11,000 in mild disease, £132,419 in moderate disease, and £221,797 in advanced JoHD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The proportion of indirect costs to families and carers was 64% for mild disease and 17% for advanced disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Family financial and care needs: ICER stakeholder input
At-risk family members: genetic discrimination in insurance
“Discrimination was reported by 93 respondents (39.9%). Reported experiences occurred most often in insurance (29.2%), family (15.5%), and social (12.4%) settings.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Family history of Huntington's disease, rather than the result of genetic testing, was the main reason given for experiences of genetic discrimination.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Across all three countries, a total of 46.2% of respondents report genetic discrimination or stigma based on either their family history of HD or genetic testing for the HD gene mutation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We report on the overall incidence of discrimination and stigma in the domains of insurance (25.9%), employment (6.5%), relationships (32.9%), and other transactions (4.6%) in the United States, Canada, and Australia combined.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Economic impact of diagnostic testing
Cost of predictive genetic testing at HDSA Centers of Excellence in the United States
Predictive testing uptake among at-risk individuals
“9407 predictive tests were performed across 23 UK centres.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Using a prevalence figure of 12.3 × 10−5, the cumulative uptake of predictive testing in the 50% at-risk UK population from 1994 to 2014 was estimated at 17.4% (95% CI: 16.9–18.0%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Future therapies in HD will likely target presymptomatic individuals; therefore, identifying the at-risk population whose gene status is unknown is of significant public health value.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Fear of health insurance loss and out-of-pocket payment for testing: North America
“After enrollment, 83 individuals [8.3%] pursued genetic testing. Their greatest concern was losing health insurance, and 41.6% of them [vs. 6.7% of those who did not pursue testing; P < 0.001] reported paying out of pocket for testing or other medical services to conceal their genetic risk from their insurer/employer.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among individuals who were tested, more United States residents [46.1%] than Canadian residents [0.0%; P = 0.02] paid out of pocket for health services or genetic testing.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Insurance protections for genetic information in the United States
Access costs: travel, time away from work, and counseling
“Distance is a structural barrier, and relates to the time and travel required to access PT, the financial and other opportunity costs associated with taking time away from work and family to attend appointments and the stress of navigating urban centers.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Genetic counseling is necessary for presymptomatic or symptomatic HD genetic testing, but the lack of access to counseling because of geography or expense is a critical gap for many patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The main advantage of tele-GC was reduction in travel time for both in-person GC first (n = 16) and tele-GC first (n = 11) participants.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Testing decisions when genetic services are fully funded: Israel
Demand for predictive testing after therapeutic trial news
Reproductive genetic testing: cost-effectiveness of preimplantation genetic testing
“Cost-effectiveness analysis in a theoretical cohort of 3,851 couples, where one individual is heterozygous for Huntington disease.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In vitro fertilization preimplantation genetic testing was associated with 77 more QALYs and a cost savings of $46,394,268.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Most notably, in our theoretical cohort of couples, IVF preimplantation genetic testing resulted in 1,079 fewer Huntington disease-affected offspring.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Approaches to treatment
Current treatment options and standard of care
VMAT2 inhibitors
EHDN international guideline: first-line treatment of chorea
AAN evidence-based guideline on chorea (retired 2022): recommendation
“If HD chorea requires treatment, clinicians should prescribe tetrabenazine (up to 100 mg/day), amantadine (300-400 mg/day), or riluzole (200 mg/day) (Level B) for varying degrees of expected benefit. Occurrence of adverse events should be discussed and monitored, particularly depression/suicidality and parkinsonism with tetrabenazine and elevated liver enzymes with riluzole.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
German Neurological Society guideline: evidence for VMAT2 inhibitors and use of tetrabenazine
“The quality of data from RCTs is currently best for VMAT2 inhibitors” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The use of tetrabenazine (in combination or as monotherapy) is recommended if treatment with tiapride is either not tolerated or not efficacious.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
MDS evidence-based review of treatments for Huntington's disease
“These data supported a likely effect of deutetrabenazine on motor impairment, chorea, and dystonia and of tetrabenazine on chorea.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Data for therapeutic interventions in HD are limited and support only the use of VMAT2 inhibitors for specific motor symptoms.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Cochrane review of symptomatic treatments
“22 trials (1254 participants) were included.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Only tetrabenazine showed a clear efficacy for the control of chorea. The remaining pharmacological interventions revealed no clear effectiveness.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
HSG expert consensus: classes used for chorea in North American practice
“Despite the negative impact chorea can have on many aspects of day-to-day life, pharmacologic treatment remains underutilized in clinical practice.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The two most common medication classes used to suppress chorea are vesicular monoamine transporter 2 (VMAT2) inhibitors and antipsychotics.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Tetrabenazine: FDA-approved indication and boxed warning
Tetrabenazine: label efficacy and functional outcomes in Study 1
Tetrabenazine: depression and sedation in the placebo-controlled trial
Tetrabenazine: TETRA-HD randomized trial
“The authors randomized 84 ambulatory patients with HD to receive TBZ (n = 54) or placebo (n = 30) for 12 weeks.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“There were five study withdrawals in the TBZ group and five serious adverse events (SAEs) in four subjects (drowning suicide, complicated fall, restlessness/suicidal ideation, and breast cancer) compared with one withdrawal and no SAEs in the placebo group.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Deutetrabenazine: FDA boxed warning and label efficacy
Deutetrabenazine: First-HD randomized trial
“Treatment success, as measured by the PGIC, occurred in 23 patients (51%) in the deutetrabenazine group vs 9 (20%) in the placebo group (P = .002).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Further research is needed to assess the clinical importance of the effect size and to determine longer-term efficacy and safety.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Valbenazine: FDA boxed warning and label efficacy
Valbenazine: parkinsonism in Huntington's disease
Valbenazine: KINECT-HD randomized trial
“Of 128 randomly assigned participants, 125 were included in the full-analysis set (64 assigned to valbenazine, 61 assigned to placebo) and 127 were included in the safety-analysis set (64 assigned to valbenazine, 63 assigned to placebo).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“No suicidal behaviour or worsening of suicidal ideation was reported in participants treated with valbenazine.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
HDSA physician's guide: indications for pharmacologic treatment of chorea
Antipsychotics
EHDN international guideline: second-generation neuroleptics for chorea and psychiatric symptoms
German Neurological Society guideline: tiapride as first-line antichoreic treatment
“Because of the favorable profile of side effects, in particular with regard to extrapyramidal (akathisia, Parkinsonism) and behavioral (depression) symptoms, the consensus in the Delphi group was that tiapride should be considered as first line treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Comparative studies (comparing head-to-head compounds for their ability to suppress hyperkinesias short- and long-term) are unavailable.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
AAN guideline (retired 2022): insufficient data for neuroleptics
HDSA physician's guide: off-label neuroleptics for chorea
International expert survey: first-choice antichoreic drug by region
“However, the experts did not agree on first choice of chorea drug, with the majority of experts in Europe favoring an antipsychotic drug (APD), and a near equal split in first choice between an APD and tetrabenazine (TBZ) among experts from North America and Australia.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Antidepressants and other psychiatric pharmacotherapy
EHDN international guideline: depression, irritability, and anxiety
HDSA physician's guide: pharmacotherapy for depression
German Neurological Society guideline: psychiatric symptoms
Expert-based consensus guidelines on agitation, anxiety, apathy, psychosis, and sleep disorders
“An international committee of 11 multidisciplinary experts proposed a series of statements regarding the description and management of each symptom.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“High-level agreement (≥85% experts strongly agreed or agreed) was reached for 107 of the 110 statements that have been incorporated into the expert-based clinical recommendations presented herein.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Systematic review of pharmacological treatment of neuropsychiatric symptoms
“Fifteen articles qualified for critical evaluation: 10 randomized controlled trials (RCTs) (five placebo-controlled and five cross-over) and five open label studies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“As a result, convincing evidence that could guide clinical practice is lacking.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Rehabilitation and nutritional therapies
EHDN international guideline: physiotherapy and exercise
EHDN international guideline: speech and language therapy and nutrition
EHDN international guideline: cognitive symptoms
Physical therapy clinical recommendations
“We recommend the following specific physical therapy interventions for people with HD: aerobic exercise (grade A evidence), alone or in combination with resistance training to improve fitness and motor function, and supervised gait training (grade A evidence) to improve spatiotemporal features of gait.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
German Neurological Society guideline: speech and occupational therapy
“Therefore, involving speech therapists in the multidisciplinary care of HD patients is essential.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Symptom-based psychosocial interventions such as psychological procedures, occupational therapy, and physical activity are recommended to stabilize and maintain everyday functions.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Limitations of current therapies
Summary
In a review of disease-modifying interventions, none of the pharmacological interventions proved effective as a disease-modifying therapy for HD, and the Huntington's Disease Society of America states that there is currently no cure or treatment that can halt, slow, or reverse progression of the disease.
- Chorea: in a review of 22 trials (1254 participants), only tetrabenazine showed clear efficacy for the control of chorea. An evidence-based review concluded that the data support only the use of VMAT2 inhibitors for specific motor symptoms. The prescribing information for tetrabenazine, deutetrabenazine, and valbenazine states that each can increase the risk of depression and suicidal thoughts and behavior in patients with HD, and tetrabenazine is contraindicated in patients who are actively suicidal or have untreated or inadequately treated depression. In the 12-week placebo-controlled tetrabenazine study, 10 of 54 patients (19%) reported depression or worsening depression compared with none of 30 placebo-treated patients; Total Chorea Scores returned to baseline at the Week 13 follow-up, 1 week after discontinuation, and measures of functional capacity and cognition showed no difference from placebo. The valbenazine prescribing information states that drug-induced parkinsonism can cause more functional disability than untreated chorea for some patients. Side effects of neuroleptics include apathy, sedation, akathisia, worsening of voluntary motor control, tardive dyskinesia, and neuroleptic malignant syndrome. One publication states that pharmacologic treatment of chorea remains underutilized in clinical practice.
- Psychiatric symptoms: the evidence-based review found no eligible evidence to support specific treatments for depression, psychosis, irritability, apathy, or suicidality. A review of fifteen articles concluded that convincing evidence to guide practice is lacking, and one guideline states that its recommendations on mental health problems are based on expert opinion.
- Cognitive symptoms: one guideline recommends no pharmacological treatment for cognitive symptoms.
- Nonpharmacological care: the evidence-based review found no eligible evidence to support physiotherapy, occupational therapy, exercise, dietary, or surgical treatments.
- Evidence base: among 376 therapeutic studies conducted between 1965 and 2015, the authors of that guideline found one grade A study.
Summary: investigational therapies and regulatory history of ifezuntirgene inilparvovec
- Tominersen: in GENERATION HD1, treatment was stopped in March 2021 on the basis of an independent data monitoring committee's benefit-risk assessment, and the cUHDRS change at week 69 in the every-8-week group was significantly worse than placebo (−0.54 points, adjusted P=0.001). In GENERATION HD2, reductions in mHTT protein and NfL in 301 participants did not translate into a meaningful improvement in clinical outcomes, and Roche discontinued clinical development of tominersen.
- Pridopidine: the primary and key secondary endpoints (change in TFC and cUHDRS at week 65) of the phase III PROOF-HD study were not met in the overall population. In its questions and answers on the withdrawal of the marketing authorisation application for pridopidine (Nurzigma), the European Medicines Agency noted that the validity and relevance of the subgroup results in patients not treated with antidopaminergic medicines had not been demonstrated.
- Ifezuntirgene inilparvovec (AMT-130): the sponsor stated at its BLA submission that there are currently no approved therapies to delay the onset or slow the progression of HD. The sponsor reported that, at an RMAT Type B meeting, the FDA agreed that Phase I/II data compared with a natural history external control may serve as the primary basis for a BLA submission under the Accelerated Approval pathway. After a pre-BLA meeting held on October 29, 2025, the FDA conveyed that the Phase I/II data were currently unlikely to provide the primary evidence to support a BLA submission. Final minutes of a Type A meeting held on January 30, 2026 stated that the FDA could not agree that the Phase I/II data compared with an external control were sufficient, and the FDA strongly recommended a prospective, randomized, double-blind, sham surgery-controlled study. After a subsequent Type B meeting, the FDA communicated that the 3-year analysis would be acceptable as the primary basis of a BLA for accelerated approval. The third quarter 2026 Form 10-Q states both that the submission was announced in September 2026 and that the BLA was submitted in August 2026 and accepted for review in October 2026; it reports the acceptance as announced on November 2, 2026. The application was granted Priority Review with a PDUFA target action date of May 1, 2027, and the 48-month topline results were not part of the BLA.
Absence of disease-modifying therapy
Tetrabenazine: contraindication in depression
Limited trial evidence in a rare disease
Investigational HTT lowering: tominersen phase 3 treatment stopped, with worse cUHDRS change at the every-8-week regimen
“On the basis of an overall benefit–risk assessment by an independent data monitoring committee, treatment was stopped in March 2021” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In the every-8-week tominersen group, the mean change from baseline in the score on the cUHDRS at week 69 was significantly worse than that in the placebo group (−0.54 points, adjusted P=0.001)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The role of antisense oligonucleotide–related toxic effects (possibly inflammatory in nature), as compared with total HTT lowering, on the outcomes observed in GENERATION HD1 cannot be distinguished, given the close relationship between drug exposure and HTT lowering.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Place in treatment, anticipated use, and care setting
Summary: studied population and anticipated use
- Studied population: the U.S. Phase I/II study and the European Phase Ib/II study use the same early manifest criteria, enrolling males and females aged 25 to 65 years with a definitive clinical diagnosis of early manifest HD and a CAG repeat of ≥40. Key eligibility criteria in one presentation included a total functional capacity of 9-13, a diagnostic confidence level of 3 or 4, HD medications stable for the prior 3 months, and striatal volumes exceeding specified minima (putamen ≥ 2.5 cm3/side; caudate ≥ 2.0 cm3/side).
- Anticipated use: the sponsor states that no available therapy can delay onset or slow progression, and that available symptomatic treatments are only transiently effective and often associated with significant side effects. The sponsor's target profile is a one-time administration of a disease-modifying therapy into the striatum. ICER's assessment names usual symptomatic care (treatment for movement disorders, psychiatric and mood symptoms, physical therapy) as the comparator. A public comment asked ICER to incorporate HD staging (ISS-2 and ISS-3) into the scope, and authors of the HD Integrated Staging System state that it could facilitate trials in populations before clinical motor diagnosis.
Summary: care setting
- Administration: in the Phase I/II studies, each treated patient received a single administration through MRI-guided, convection-enhanced stereotactic neurosurgical delivery directly into the striatum (caudate and putamen).
- Access to specialty care: clinical experts told ICER that about 30% of patients with HD receive specialty care with a movement disorders neurologist, and half of those receive care at an HD Center of Excellence, which raises concern about access to new treatments offered only at specialty centers. A public comment to ICER stated that access is limited to a few neurosurgical centers, that effects beyond four years are unknown, and that there are no retreatment data.
- Centers of Excellence: there are 60 HDSA Centers of Excellence and 9 Partner Sites covering 37 States plus the District of Columbia, each providing a multidisciplinary team approach. HDSA's comment to ICER states that these centers can inform the treatment burden, access barriers, caregiver requirements, travel, follow-up, and infrastructure needed to deliver a new therapy.
- Payer analog: Aetna's criteria for eladocagene exuparvovec-tneq (Kebilidi) require precertification, prescription by or in consultation with a neurologist, geneticist, or physician specializing in inherited metabolic diseases, and administration in a medical center that specializes in stereotactic neurosurgery; the policy states that gene and cellular therapies must be administered at an Aetna GCIT Network unless the member's plan has elected otherwise.
Sponsor statement: absence of disease-modifying therapy and limits of symptomatic treatment
Sponsor target profile: one-time administration into the striatum
Comparator care in the ICER assessment: usual symptomatic care
Access to specialty neurology care: clinical expert input to ICER
HDSA Centers of Excellence and delivery of a new therapy: HDSA comment to ICER
Neurosurgical center access, retreatment, and disease stage: public comment to ICER on the draft scope
Care setting analog: Aetna criteria for the gene therapy Kebilidi, administered at a stereotactic neurosurgery center
Target stages: HD Integrated Staging System
HD-ISS as a framework for earlier intervention
Care setting: MRI-guided neurosurgical administration of AMT-130
Specialist care setting: HDSA Centers of Excellence
Heterogeneity of treatment effect
Summary
- Dose: the sponsor reports a difference between doses at 48 months in two statements. The third quarter 2026 release states that high-dose patients showed 1.1 points less decline on cUHDRS and 0.33 points less decline on TFC than low-dose patients. The four-year data release reports mean changes from baseline of –0.91 (high dose) and −1.94 (low dose) on cUHDRS, a difference of 1.03, and −0.30 and −0.70 on TFC, a difference of 0.40.
- Striatal volume: in natural history data presented with the AMT-130 analyses, baseline striatal volume predicted clinical progression in TRACK-HD and predicted cUHDRS decline in the absence of other covariates, and was no longer predictive of cUHDRS or TFC decline when propensity score adjustments were applied. A fourth cohort of six participants with lower striatal volumes than participants in previous cohorts received high-dose AMT-130, with dosing completed in the fourth quarter of 2025.
- Planned analyses: ICER's research protocol plans, data permitting, to evaluate treatment effect modification by HD stage (HD-ISS stages 2 and 3), concomitant antidopaminergic medication, and striatal volume. ICER's model analysis plan states that no heterogeneity and subgroup analyses are planned because currently available trial data are insufficient to support them. A public comment from Prilenia identified concomitant antidopaminergic medications as a pharmacologically important covariate that a chance imbalance in small studies can shift.
- Natural history: in a progression model, TFC progression in individuals with HD-ISS 2 is not expected to differ from that in HD-ISS 3, and progression rates correlate weakly between clinical scores. In 960 participants, longer disease duration and better cognitive status at baseline were associated with less rapid TFC decline.
- Other HD therapies: exploratory GENERATION HD1 analyses suggested benefit in younger participants with lower disease burden, but in GENERATION HD2 the biomarker effects did not translate into a meaningful clinical improvement. For pridopidine, post hoc analyses suggested benefit in participants not receiving antidopaminergic medications, and the European Medicines Agency noted that the validity and relevance of the subgroup results had not been demonstrated.
Dose response: high dose compared with low dose at 48 months
Baseline striatal volume as a predictor of progression in natural history data
Planned evaluation of treatment effect modification by subpopulation
Heterogeneity and subgroup analyses not planned
Antidopaminergic medication as an effect modifier: public comment by Prilenia
Progression by subpopulation and endpoint: disease progression model
“For instance, PIN and CAP can effectively enrich the population with patients more likely to progress, particularly when using TFC (Figure 5, A and B).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Moreover, when using TFC as an end point, the progression rate in individuals with HD-ISS = 2 is not expected to be different from the rate in those with HD-ISS = 3, in contrast to other clinical measurements such as SMDT (Figure 5C).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, the weak correlation in progression rates between different clinical scores indicates that patients likely to progress based on one score may not necessarily progress based on other scores.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Baseline covariates of functional decline: cohort of 960 participants
“In multivariate analysis (n = 960), longer disease duration and better cognitive status at baseline were associated with a less rapid rate of decline in TFC score, whereas depressive symptomatology was the only factor associated with more rapid decline on the IS score.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Tominersen: exploratory subgroup finding tested in GENERATION HD2
“GENERATION HD2 was initiated following exploratory analyses of the phase III GENERATION HD1 study, which suggested that younger participants with lower disease burden might derive benefit from lower-dose, less frequent administration of tominersen.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“After completion of the planned 16-month treatment period in all 301 participants, top-line analyses showed that tominersen was well tolerated and achieved significant reductions in mHTT protein and NfL concentrations compared with placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, these biomarker effects did not translate into a meaningful improvement in clinical outcomes, and Roche therefore discontinued further clinical development of tominersen.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pridopidine: post hoc subgroup without antidopaminergic medication
“PRECISE-HD seeks to build on findings from numerous large trials of pridopidine in HD that failed to demonstrate efficacy, most recently the phase III PROOF-HD study (NCT04556656),” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Although the primary and key secondary endpoints (change in TFC and cUHDRS at week 65) were not met in the overall study population, post-hoc and sensitivity analyses suggested potential benefit among participants who were not receiving antidopaminergic medications.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pridopidine (Nurzigma): regulator assessment of the subgroup analyses
Care management intervention strategies
Summary
- Procedure and monitoring analogs: the prescribing information for Kebilidi, a product administered by stereotactic neurosurgery, directs monitoring for procedure-related adverse events, including continuous cardiorespiratory monitoring during hospitalization, and the FDA review states that procedural complications can be mitigated by post-procedural monitoring. Aetna considers brain MRI for stereotactic planning and intraoperative navigation medically necessary for members being considered for Kebilidi.
- Long-term follow-up: FDA guidance recommends long-term follow-up of up to five years for AAV vectors, with a risk-based approach to duration for vectors capable of long term expression without integration, such as AAV.
- Multidisciplinary care: a multidisciplinary position paper recommends a multidisciplinary team, an individualised care and treatment plan for every patient and family, and a case manager or coordinator. The Huntington's Disease Society of America states that no one doctor or caregiver should manage all aspects of an HD case, and that the goals of treatment are to reduce the burden of symptoms, maximize function, and optimize quality of life. HDSA Centers of Excellence provide neurologists, psychiatrists, social workers, therapists, counselors, and other professionals.
- Advance care planning: one guideline describes advance care planning as essential, including discussion of alternative feeding methods, and another recommends documenting living wills and care directives early and social worker support for financial assistance. In one study, engaging in advance care planning did not cause untoward effects on health-related quality of life or suicidal thoughts and behavior (STB), whose lifetime prevalence in HD approaches 30%.
- Palliative care: a review included 38 of 333 articles and found a low level of evidence for most topics. One publication states that referral to palliative care should be strongly considered for patients with pain, anxiety, sleep disturbances, and difficulty coping with the diagnosis.
Post-procedural monitoring after Kebilidi administration: label and FDA review
Pre-procedure imaging in Aetna criteria for Kebilidi: stereotactic planning MRI
Long-term follow-up after AAV gene therapy: FDA guidance
EHDN multidisciplinary position paper: managed care network and case manager
“The multidisciplinary team should be composed of different professionals who work closely together and interact within the group. It is also important to establish an individualised care and treatment plan for every single case of a patient and family. A case manager or coordinator may facilitate the work of the multidisciplinary team.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This position paper reveals that there are key essential professional groups involved in the MDT who do not have an HD guideline available, like psychologists, social workers, nurses, case managers and general practitioners.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
HDSA physician's guide: team care and Centers of Excellence
HDSA Centers of Excellence: team composition
Advance care planning: EHDN guideline
Advance care planning and psychosocial support: German Neurological Society guideline
“Early in the disease process, it is recommended to document living wills and care directives” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Moreover, there should be support from a social worker to navigate the complex bureaucracy to apply for and obtain financial assistance and support for care needs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Advance care planning: multicenter HDQLIFE study
Palliative care in advanced disease: scoping review
“Our search resulted in 333 articles, 38 of which were included.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Most literature was underpinned by a low level of evidence, except for the topics on social care (Level III-V), advance care planning (Level II-V) and end-of-life needs assessments (Level II-III).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Other product development or post-marketing obligations required by the FDA
Not applicable.
Ongoing post-approval monitoring
Not applicable.
Expected outcomes of therapy
Summary
- Durability: ICER's model analysis plan assumes that the treatment effect remains constant over the lifetime horizon and does not model discontinuation of a one-time gene therapy. Clinical experts noted that because neurons do not divide, the treatment effect may persist, while substantial uncertainty remains around long-term efficacy. ICER models TFC because there is no established mapping from the cUHDRS to costs, utilities, or mortality.
- Endpoints: a decline of 1.2 points on the cUHDRS is recommended as an estimate of meaningful within-patient decline in early manifest HD. The sponsor reports that the FDA continued to support the cUHDRS as an acceptable registrational, intermediate clinical endpoint for accelerated approval, and a votoplam trial uses change from baseline up to month 36 in the cUHDRS as its primary endpoint. ICER's outcomes of interest include procedure-related adverse events (headache, complications, pain) and post lumbar puncture syndrome.
- Interpretation of external comparisons: a placebo response in cognitive scores also influences the cUHDRS, and comparisons of trial data with retrospective natural history studies can mislead in distinguishing placebo response from drug effect. FDA draft guidance states that changes in the understanding of a disease's natural history can introduce bias in an externally controlled trial. Of forty-five FDA approvals that accepted external control data, retrospective natural history data were the most common source (44%) and 87% used an objective primary endpoint. Commentators cite a possible medical response bias from more frequent clinic visits, unmatched differences such as caudate and putamen size, and very small numbers of treated patients at longer follow-up, and state that assumptions about how long the benefit lasts will heavily shape modeled results.
- Modeled long-term outcomes: in one model, hypothetical disease-modifying treatments led to cost savings in the PFD population and increased costs in the SF1 and SF2 populations by prolonging time spent in progressive HD states.
Durability of a one-time gene therapy: ICER modeling assumption and clinical expert input
Link between cUHDRS and long-term outcomes: ICER rationale for modeling Total Functional Capacity
Procedure-related outcomes in the ICER assessment
Placebo and practice effects when trial data are compared with natural history
“Of interest, the cognitive scores (SDMT, SWR) exhibited an even stronger placebo response that was sustained after the dosing period of the trial ended.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“It is important to note that these effects also significantly influence the cUHDRS score, given that it is derived from a linear relationship between TFC, TMS, SDMT score, and SWR score.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, our analysis also emphasizes the potential for misleading interpretations when comparing trial data with retrospective natural history studies, particularly in distinguishing placebo response from drug effect.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Interpretation of externally controlled comparisons: FDA draft guidance
External controls in FDA approvals, 2000 to 2019: sources and endpoints
“Forty-five approvals were identified where FDA accepted external control data in their benefit/risk assessment” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Retrospective natural history data, including retrospective reviews of patient records, was the most common source of external control (44%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The vast majority (87%) of cases identified utilized an objective measure as a primary endpoint.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For the few cases where the endpoint was subjective, the benefit was so large it was unlikely to be due to chance alone.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Independent commentary on the natural history comparator and durability of AMT-130
Natural history-based evidence and assumed duration of benefit: Prilenia comment to ICER
Composite clinical progression measure in early Huntington's disease
“Use of a composite motor, cognitive, and global functional clinical outcome measure in HD provides an improved measure of clinical progression more related to measures of progressive brain atrophy and provides an opportunity for enhanced clinical trial efficiency relative to currently used individual motor, cognitive, and functional outcome measures.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Clinically meaningful change on the cUHDRS
Regulatory acceptance of cUHDRS as an intermediate clinical endpoint: sponsor-reported FDA feedback
Phase 3 disease-modifying trial endpoint: votoplam INVEST-HD
Time to functional decline as an endpoint
Cognitive endpoints and regulatory meaningfulness
Aims of disease-modifying treatment and modeled long-term outcomes
“Potential disease-modifying treatments (DMTs) such as gene therapy (GTx), antisense oligonucleotides (ASOs), and small molecule–based therapeutic approaches aim to provide long-term health benefits for people with HD by slowing down, arresting, or even reverting disease progression.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Although hypothetical DMTs led to cost savings in the PFD population by delaying the cost burdens of functional decline, they increased costs in SF1 and SF2 populations by prolonging time spent in expensive progressive HD states.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Expected outcomes of symptomatic chorea treatment
“By integrating pharmacologic therapy with multidisciplinary care and holistic, goal-oriented communication about the impact of chorea, clinicians can meaningfully improve safety, independence, and quality of life for individuals and families affected by HD.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote